Remdesivir
was the first antiviral drug that received emergency
use authorization from the United States Food and Drug Administration
and is now formally approved to treat COVID-19. Remdesivir is a nucleotide
analogue that targets the RNA-dependent RNA polymerase (RdRp) of coronaviruses,
including SARS-CoV-2. The solution of multiple RdRp structures has
been one of the main axes of research in the race against the SARS-CoV-2
virus. Several hypotheses of the mechanism of inhibition of RdRp by
remdesivir have been proposed, although open questions remain. This
work uses molecular dynamics simulations to explore the impact of
remdesivir and two analogues as incoming nucleotides and of up to
four incorporations of remdesivir along the primer strand on RdRp.
The simulation results suggest that the overall structure and the
dynamical behavior of RdRp are destabilized by remdesivir and the
two analogues in the incoming position. The incorporation of remdesivir
along the primer strand impacts specific non-bonded interactions between
the nascent RNA and the polymerase subunit, as well as the overall
dynamical networks on RdRp. The strongest impact on the structure
and dynamics are observed after three incorporations, when remdesivir
is located at position −A3, in agreement with previously reported
experimental and computational results. Our results provide atomic-level
details of the role played by remdesivir on the disruption of RNA
synthesis by RdRp and the main drivers of these disruptions.